We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties. You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies. In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Catalent (CTLT) Declines on Profit Warnings and CFO Exit
Read MoreHide Full Article
Catalent Inc.’s shares have been declining since Friday last week, following its issuance of profit warning for the third quarter of fiscal 2023. CTLT also announced the departure of its chief operating officer (CFO) and the appointment of its president, division head for Clinical Development & Supply as interim CFO.
Business Update
Catalent has cautioned about its profits taking a hit in third-quarter fiscal 2023. The company attributes this decline to productivity issues and higher-than-expected costs experienced at three of its facilities. However, Catalent is confident about its ability to overcome these challenges and attain sustainable growth in the future.
The company has appointed Ricky Hopson as interim CFO, with immediate effect. Hopson was previously serving as CTLT’s senior vice president and corporate controller, and has been with the company for more than 20 years. He will succeed Thomas Castellano.
The company also expressed its confidence in Hopson's ability to effectively lead the finance department during this transitional period.
Stock Movement
The Catalent stock has declined more than 30% since Apr 13. However, Catalent’s shares are up 1% so far this year against the industry’s 1.8% decline. The S&P 500 Index has gained 8.4% in the same time period.
Image Source: Zacks Investment Research
Conclusion
CTLT’s business update highlights the challenges that it is facing due to rise in costs and operational challenges.
Catalent is confident about overcoming these challenges and achieving sustainable growth in the future. The appointment of Ricky Hopson as interim CFO also demonstrates the company's commitment to continuity and effective leadership during this transitional period. As CTLT awaits a permanent CFO and addresses its operational challenges, investors will look for improvements in the company’s financial performance.
Zacks Rank & Stocks to Consider
Catalent currently carries a Zacks Rank #3 (Hold).
Becton, Dickinson and Company has an estimated long-term growth of 7.8%. BDX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6.47%.
The company’s shares have gained 0.8% compared with the industry’s 5.9% growth in the past three months.
Henry Schein has an estimated long-term growth of 8.1%. HSIC’s earnings surpassed estimates in three of the trailing four quarters and met the same once, the average surprise being 2.97%.
The company’s shares have gained 2.6% compared with the industry’s 5.9% growth in the past three months.
The Cooper Companies has an estimated long-term growth of 11%. COO’s earnings missed estimates in three of the trailing four quarters and beat the same once, the average negative surprise being 1.82%.
The company’s shares have gained 10.1% compared with the industry’s 5.9% growth over the past three months.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Catalent (CTLT) Declines on Profit Warnings and CFO Exit
Catalent Inc.’s shares have been declining since Friday last week, following its issuance of profit warning for the third quarter of fiscal 2023. CTLT also announced the departure of its chief operating officer (CFO) and the appointment of its president, division head for Clinical Development & Supply as interim CFO.
Business Update
Catalent has cautioned about its profits taking a hit in third-quarter fiscal 2023. The company attributes this decline to productivity issues and higher-than-expected costs experienced at three of its facilities. However, Catalent is confident about its ability to overcome these challenges and attain sustainable growth in the future.
Catalent, Inc. Price
Catalent, Inc. price | Catalent, Inc. Quote
Interim CFO Appointment
The company has appointed Ricky Hopson as interim CFO, with immediate effect. Hopson was previously serving as CTLT’s senior vice president and corporate controller, and has been with the company for more than 20 years. He will succeed Thomas Castellano.
The company also expressed its confidence in Hopson's ability to effectively lead the finance department during this transitional period.
Stock Movement
The Catalent stock has declined more than 30% since Apr 13. However, Catalent’s shares are up 1% so far this year against the industry’s 1.8% decline. The S&P 500 Index has gained 8.4% in the same time period.
Image Source: Zacks Investment Research
Conclusion
CTLT’s business update highlights the challenges that it is facing due to rise in costs and operational challenges.
Catalent is confident about overcoming these challenges and achieving sustainable growth in the future. The appointment of Ricky Hopson as interim CFO also demonstrates the company's commitment to continuity and effective leadership during this transitional period. As CTLT awaits a permanent CFO and addresses its operational challenges, investors will look for improvements in the company’s financial performance.
Zacks Rank & Stocks to Consider
Catalent currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Becton, Dickinson and Company (BDX - Free Report) , Henry Schein (HSIC - Free Report) and The Cooper Companies (COO - Free Report) . While both BDX and COO carry a Zacks Rank #2 (Buy) at present, HSIC sports a Zacks #1 Rank (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Becton, Dickinson and Company has an estimated long-term growth of 7.8%. BDX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6.47%.
The company’s shares have gained 0.8% compared with the industry’s 5.9% growth in the past three months.
Henry Schein has an estimated long-term growth of 8.1%. HSIC’s earnings surpassed estimates in three of the trailing four quarters and met the same once, the average surprise being 2.97%.
The company’s shares have gained 2.6% compared with the industry’s 5.9% growth in the past three months.
The Cooper Companies has an estimated long-term growth of 11%. COO’s earnings missed estimates in three of the trailing four quarters and beat the same once, the average negative surprise being 1.82%.
The company’s shares have gained 10.1% compared with the industry’s 5.9% growth over the past three months.